SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers
{{output}}
Sunesis Pharmaceuticals Inc, under license from Dainippon Sumitomo Pharma Co Ltd, is developing SNS-595, a naphthyridine cell cycle inhibitor and apoptosis stimulator, for the potential treatment of a variety of solid and hematological malignancies. Phase I cl... ...
